This page brings together the Agency's latest information on cancer. It lists:
This is a summary of the European public assessment report (EPAR) for Ninlaro. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It...
This is a summary of the European public assessment report (EPAR) for Bortezomib Sun. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of...
Velcade is a cancer medicine that is generally used in combination with other medicines to treat multiple myeloma, a blood cancer, in: adults whose disease is getting worse after at least one other...
This is a summary of the European public assessment report (EPAR) for Herzuma. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It...
Braftovi is a medicine for treating certain cancers when their cells have a mutation (change) in their genes called 'BRAF V600'. Braftovi is used in combination with another medicine, binimetinib to...
Fifteen new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended 15 medicines for approval at its December 2020 meeting. The Committee recommended granting a conditional marketing authorisation for Enhertu (...
Ten new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended ten medicines for approval at its October 2020 meeting. The Committee recommended granting a conditional marketing authorisation for Tecartus* (autologous...
On Thursday, 29 October, EMA is hosting a symposium to discuss new approaches to facilitating and using input from cancer patients to inform medicine development and regulatory decision-making. The agenda of the symposium , which will be held...
EMA is reminding physicians to use Tecentriq (atezolizumab) only in combination with nab-paclitaxel and not with conventional paclitaxel when treating patients with locally advanced or metastatic triple-negative breast cancer that cannot be...
EMA has recommended that the use of Yondelis (trabectedin) in treating ovarian cancer remain unchanged following a review of a study that investigated Yondelis as a third-line treatment in patients with ovarian cancer. However, the study results...
EMA has recommended that patients should be tested for the lack of the enzyme dihydropyrimidine dehydrogenase (DPD) before starting cancer treatment with fluorouracil given by injection or infusion (drip) or with the related medicines, capecitabine...
The European Medicines Agency is hosting a symposium to explore themes such as the natural...
Update: Due to a number of cancellations of participants, this workshop is postponed to later in...
The aim of the workshop is to investigate the feasibility of using disease registries for cancer...
The innovation and biomarkers in cancer drug development (IBCD) 2018 event will embrace the full...